DE60004181T2 - Behandlung der pulmonalen hypertension durch inhalation von benzinden-prostaglandine - Google Patents
Behandlung der pulmonalen hypertension durch inhalation von benzinden-prostaglandine Download PDFInfo
- Publication number
- DE60004181T2 DE60004181T2 DE60004181T DE60004181T DE60004181T2 DE 60004181 T2 DE60004181 T2 DE 60004181T2 DE 60004181 T DE60004181 T DE 60004181T DE 60004181 T DE60004181 T DE 60004181T DE 60004181 T2 DE60004181 T2 DE 60004181T2
- Authority
- DE
- Germany
- Prior art keywords
- baseline
- aerosolized
- pulmonary
- intravenous
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010020772 Hypertension Diseases 0.000 title description 9
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims abstract description 133
- -1 benzindene prostaglandins Chemical class 0.000 claims abstract description 32
- 208000002815 pulmonary hypertension Diseases 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- KXYGKDBONOVZOM-UHFFFAOYSA-N 1h-cyclopenta[a]naphthalene Chemical class C1=CC=CC2=C3CC=CC3=CC=C21 KXYGKDBONOVZOM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 241001494479 Pecora Species 0.000 abstract description 26
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 4
- 238000001990 intravenous administration Methods 0.000 description 57
- 230000000694 effects Effects 0.000 description 45
- DJKDIKIDYDXHDD-IGUVKOCZSA-N U-44069 Chemical compound C1O[C@@H]2[C@H](C\C=C/CCCC(O)=O)[C@@H](/C=C/[C@@H](O)CCCCC)[C@H]1C2 DJKDIKIDYDXHDD-IGUVKOCZSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- 230000036593 pulmonary vascular resistance Effects 0.000 description 32
- 239000000443 aerosol Substances 0.000 description 27
- 231100000673 dose–response relationship Toxicity 0.000 description 23
- 230000004872 arterial blood pressure Effects 0.000 description 22
- 210000002216 heart Anatomy 0.000 description 22
- 230000002685 pulmonary effect Effects 0.000 description 21
- 230000000747 cardiac effect Effects 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 16
- 238000001802 infusion Methods 0.000 description 16
- 210000001147 pulmonary artery Anatomy 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 230000002792 vascular Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000001746 atrial effect Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000006199 nebulizer Substances 0.000 description 6
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Chemical class 0.000 description 5
- 238000012387 aerosolization Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 206010039163 Right ventricular failure Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000037812 secondary pulmonary hypertension Diseases 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000004088 pulmonary circulation Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- XZFRIPGNUQRGPI-WLPVIMDJSA-N Carbacyclin Chemical class C1\C(=C\CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WLPVIMDJSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021133 Hypoventilation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940001440 flolan Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 208000005907 mitral valve insufficiency Diseases 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003173 prostaglandin H2 derivatives Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12499999P | 1999-03-18 | 1999-03-18 | |
| US124999P | 1999-03-18 | ||
| PCT/US2000/040040 WO2000054758A2 (en) | 1999-03-18 | 2000-03-17 | Method for delivering benzidine prostaglandins by inhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60004181D1 DE60004181D1 (de) | 2003-09-04 |
| DE60004181T2 true DE60004181T2 (de) | 2004-04-15 |
Family
ID=22417774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60004181T Expired - Lifetime DE60004181T2 (de) | 1999-03-18 | 2000-03-17 | Behandlung der pulmonalen hypertension durch inhalation von benzinden-prostaglandine |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6521212B1 (enExample) |
| EP (1) | EP1161234B1 (enExample) |
| JP (2) | JP4819224B2 (enExample) |
| KR (1) | KR100750384B1 (enExample) |
| CN (1) | CN1196479C (enExample) |
| AT (1) | ATE245979T1 (enExample) |
| AU (1) | AU4082700A (enExample) |
| CA (1) | CA2365890C (enExample) |
| DE (1) | DE60004181T2 (enExample) |
| DK (1) | DK1161234T3 (enExample) |
| ES (1) | ES2203449T3 (enExample) |
| PT (1) | PT1161234E (enExample) |
| WO (1) | WO2000054758A2 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6521212B1 (en) * | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| DE10163697A1 (de) * | 2001-12-21 | 2003-07-03 | Studiengesellschaft Kohle Mbh | Reversible Speicherung von Wasserstoff mit Hilfe von dotierten Alkalimetallaluminiumhydriden |
| US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
| US7811606B2 (en) | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
| US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| CN102697790A (zh) * | 2003-05-22 | 2012-10-03 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20090124697A1 (en) | 2003-12-16 | 2009-05-14 | United Therapeutics Corporation | Inhalation formulations of treprostinil |
| CN1917866B (zh) * | 2003-12-16 | 2010-12-15 | 联合治疗公司 | 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途 |
| US7199157B2 (en) * | 2003-12-16 | 2007-04-03 | United Therapeutics Corporation | Use of treprostinil to improve kidney functions |
| DE602005020269D1 (de) * | 2004-04-12 | 2010-05-12 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren |
| US20100130500A1 (en) * | 2004-12-08 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2007067570A1 (en) * | 2005-12-05 | 2007-06-14 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of disease |
| US8747897B2 (en) | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
| CA2654492C (en) * | 2006-05-15 | 2017-06-27 | United Therapeutics Corporation | Treprostinil administration using a metered dose inhaler |
| DE102006026786A1 (de) | 2006-06-07 | 2007-12-13 | Joachim Kern | Dosierinhalator |
| US20090036465A1 (en) * | 2006-10-18 | 2009-02-05 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
| WO2008089148A1 (en) * | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug |
| CA2678258A1 (en) * | 2007-02-09 | 2008-08-14 | United Therapeutics Corporation | Treprostinil treatment for interstitial lung disease and asthma |
| WO2009078965A1 (en) | 2007-12-17 | 2009-06-25 | United Therapeutics Corporation | An improved process to prepare treprostinil, the active ingredient in remodulin |
| JP6219016B2 (ja) * | 2008-05-08 | 2017-10-25 | ユナイテッド セラピューティクス コーポレーション | トレプロスチニル一水和物 |
| EP2330893A4 (en) * | 2008-09-25 | 2013-01-09 | Aradigm Corp | DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL |
| CN102421288B (zh) * | 2009-05-07 | 2015-04-22 | 联合治疗公司 | 前列环素类似物的固体剂型 |
| KR20160132501A (ko) | 2010-03-15 | 2016-11-18 | 유나이티드 세러퓨틱스 코오포레이션 | 폐고혈압의 치료 |
| CN103261142B (zh) | 2010-06-03 | 2014-12-10 | 联合治疗公司 | 曲前列环素的制备 |
| ES2581762T3 (es) | 2011-03-02 | 2016-09-07 | United Therapeutics Corporation | Síntesis de producto intermedio para la producción de treprostinil |
| CN103193627B (zh) | 2012-01-10 | 2016-04-20 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
| CN103193626B (zh) | 2012-01-10 | 2016-05-11 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
| US9387214B2 (en) | 2012-01-13 | 2016-07-12 | United Therapeutics Corporation | Method of identifying therapies for pulmonary hypertension |
| WO2014085813A1 (en) * | 2012-11-30 | 2014-06-05 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| WO2014159050A1 (en) | 2013-03-14 | 2014-10-02 | United Therapeutics Corporation | Solid forms of treprostinil |
| EP2970081A4 (en) | 2013-03-15 | 2016-10-12 | United Therapeutics Corp | SALTS OF TREPROSTINIL |
| WO2014160638A1 (en) | 2013-03-25 | 2014-10-02 | United Therapeutics Corporation | Process of making prostacyclin compounds with linker thiol and pegylated forms |
| US9469600B2 (en) | 2013-10-25 | 2016-10-18 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| ES2908142T3 (es) | 2014-06-13 | 2022-04-27 | United Therapeutics Corp | Formulaciones de treprostinil |
| CN107108427A (zh) | 2014-10-20 | 2017-08-29 | 联合治疗学有限公司 | 用于制备前列环素衍生物的中间体的合成 |
| US10343979B2 (en) | 2014-11-18 | 2019-07-09 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| CA2967899C (en) | 2014-12-03 | 2023-09-19 | Steadymed Ltd | Preservative-free treprostinil formulations and methods and devices for use with same |
| RU2593016C2 (ru) * | 2014-12-15 | 2016-07-27 | Федеральное государственное бюджетное учреждение науки Институт теоретической и прикладной механики им. С.А. Христиановича Сибирского отделения Российской академии наук (ИТПМ СО РАН) | Способ лечения артериальной гипертензии путем ингаляционного введения аэрозоля гипотензивного препарата |
| EP3452170A4 (en) | 2016-05-05 | 2020-04-01 | Liquidia Technologies, Inc. | TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION |
| WO2018058124A1 (en) | 2016-09-26 | 2018-03-29 | United Therapeutics Corporation | Treprostinil prodrugs |
| EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| US10799653B2 (en) | 2017-01-09 | 2020-10-13 | United Therapeutics Corporation | Aerosol delivery device and method for manufacturing and operating the same |
| US10702495B2 (en) | 2017-02-20 | 2020-07-07 | Nexien Biopharma, Inc. | Method and compositions for treating dystrophies and myotonia |
| EP3498283A1 (en) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidic derivatives of treprostinil |
| CN112739679B (zh) | 2018-09-18 | 2024-03-12 | 伊莱利利公司 | 曲前列环素的特丁胺盐 |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| MX2021003866A (es) | 2018-10-05 | 2021-09-08 | Xenotherapeutics Inc | Productos y metodos de xenotransplante. |
| CN119632930A (zh) | 2019-04-29 | 2025-03-18 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| EP3750528A1 (en) | 2019-06-11 | 2020-12-16 | Nexien Biopharma, Inc. | Compositions for treating dystrophies and myotonia |
| CN114616225A (zh) | 2019-08-23 | 2022-06-10 | 联合治疗公司 | 曲前列环素前药 |
| US11339110B2 (en) | 2019-12-19 | 2022-05-24 | Chirogate International Inc. | Efficient crystallization process for preparing ultrapure Treprostinil and crystal prepared therefrom |
| IL296567A (en) | 2020-04-17 | 2022-11-01 | United Therapeutics Corp | Terfostinil for use in the treatment of interstitial lung disease |
| AU2021289336B2 (en) | 2020-06-09 | 2025-08-28 | Mannkind Corporation | Fumaryl diketopiperidine prodrugs of treprostinil |
| US11447440B2 (en) | 2020-10-29 | 2022-09-20 | Chirogate International Inc. | Treprostinil monohydrate crystals and methods for preparation thereof |
| KR102849520B1 (ko) | 2020-12-14 | 2025-08-25 | 유나이티드 쎄러퓨틱스 코포레이션 | 트레프로스티닐 프로드러그로 질환을 치료하는 방법 |
| WO2022187352A1 (en) | 2021-03-03 | 2022-09-09 | United Therapeutics Corporation | A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp) |
| WO2023154705A1 (en) | 2022-02-08 | 2023-08-17 | United Therapeutics Corporation | Treprostinil iloprost combination therapy |
| EP4516297A4 (en) | 2022-04-29 | 2026-02-25 | Zhaoke pharmaceutical guangzhou co ltd | Treprostinil Gentle Inhalation Mist |
| EP4651879A1 (en) | 2023-01-18 | 2025-11-26 | United Therapeutics Corporation | Treatment of pulmonary arterial hypertension |
| CN121241041A (zh) | 2023-01-19 | 2025-12-30 | 联合治疗公司 | 曲前列尼尔类似物及相关制备和使用方法 |
| WO2026035705A1 (en) | 2024-08-06 | 2026-02-12 | United Therapeutics Corporation | Treating pulmonary hypertension based on novel biomarker |
| US20260166056A1 (en) | 2024-12-13 | 2026-06-18 | United Therapeutics Corporation | Treprostinil formulations and their uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338457A (en) * | 1980-02-28 | 1982-07-06 | The Upjohn Company | Composition and process |
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| US4306076A (en) * | 1980-04-23 | 1981-12-15 | The Upjohn Company | Inter-phenylene CBA compounds |
| JPS5795920A (en) * | 1980-12-04 | 1982-06-15 | Teijin Ltd | Remedy for respiratory disease |
| US4349689A (en) * | 1980-12-22 | 1982-09-14 | The Upjohn Company | Methano carbacyclin analogs |
| ZA851337B (en) * | 1984-03-08 | 1985-10-30 | Upjohn Co | Interphenylene carbacyclin derivatives |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| ATE78158T1 (de) * | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| DK299089A (da) * | 1988-06-17 | 1989-12-18 | Wellcome Found | Anvendelse af prostaglandiner til fremstilling af laegemidler |
| GB8814438D0 (en) | 1988-06-17 | 1988-07-20 | Wellcome Found | Compounds for use in medicine |
| JP2704546B2 (ja) * | 1989-04-04 | 1998-01-26 | 光利 太良 | Ａｔｌｌ治療用吸入剤 |
| US5190972A (en) * | 1992-01-27 | 1993-03-02 | The University Of Melbourne | Method of combatting cyclosporine organ toxicity with prostaglandin analogs |
| EP0611567B1 (en) * | 1992-06-12 | 2002-08-28 | Teijin Limited | Ultrafine powder for inhalation and production thereof |
| ES2214753T3 (es) * | 1997-11-14 | 2004-09-16 | United Therapeutics Corporation | Uso de 9-desoxi-2',9-alfa-metano-3-oxa-4,5,6-trinor-3,7-(1',3'-interfenilen)-13,14-dihidro-prostaglandina f1 para tratar la enfermedad vascular periferica. |
| US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
-
2000
- 2000-03-15 US US09/525,471 patent/US6521212B1/en not_active Expired - Lifetime
- 2000-03-17 AT AT00920253T patent/ATE245979T1/de active
- 2000-03-17 ES ES00920253T patent/ES2203449T3/es not_active Expired - Lifetime
- 2000-03-17 KR KR1020017011610A patent/KR100750384B1/ko not_active Expired - Lifetime
- 2000-03-17 JP JP2000604834A patent/JP4819224B2/ja not_active Expired - Lifetime
- 2000-03-17 WO PCT/US2000/040040 patent/WO2000054758A2/en not_active Ceased
- 2000-03-17 PT PT00920253T patent/PT1161234E/pt unknown
- 2000-03-17 AU AU40827/00A patent/AU4082700A/en not_active Abandoned
- 2000-03-17 CA CA2365890A patent/CA2365890C/en not_active Expired - Lifetime
- 2000-03-17 EP EP00920253A patent/EP1161234B1/en not_active Expired - Lifetime
- 2000-03-17 CN CNB008051089A patent/CN1196479C/zh not_active Expired - Lifetime
- 2000-03-17 DE DE60004181T patent/DE60004181T2/de not_active Expired - Lifetime
- 2000-03-17 DK DK00920253T patent/DK1161234T3/da active
-
2002
- 2002-08-06 US US10/212,149 patent/US6756033B2/en not_active Expired - Lifetime
-
2011
- 2011-05-30 JP JP2011119894A patent/JP2011201907A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2203449T3 (es) | 2004-04-16 |
| EP1161234A2 (en) | 2001-12-12 |
| US6756033B2 (en) | 2004-06-29 |
| CA2365890C (en) | 2010-09-21 |
| WO2000054758A2 (en) | 2000-09-21 |
| ATE245979T1 (de) | 2003-08-15 |
| DE60004181D1 (de) | 2003-09-04 |
| CN1196479C (zh) | 2005-04-13 |
| JP4819224B2 (ja) | 2011-11-24 |
| WO2000054758A3 (en) | 2001-02-08 |
| DK1161234T3 (da) | 2003-11-24 |
| AU4082700A (en) | 2000-10-04 |
| JP2011201907A (ja) | 2011-10-13 |
| CN1379665A (zh) | 2002-11-13 |
| JP2002539154A (ja) | 2002-11-19 |
| KR100750384B1 (ko) | 2007-08-17 |
| PT1161234E (pt) | 2003-12-31 |
| KR20010108352A (ko) | 2001-12-07 |
| US20030053958A1 (en) | 2003-03-20 |
| CA2365890A1 (en) | 2000-09-21 |
| EP1161234B1 (en) | 2003-07-30 |
| US6521212B1 (en) | 2003-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100750384B1 (ko) | 흡입에 의하여 벤진덴 프로스타글란딘을 투여하는 방법 | |
| DE60027985T2 (de) | Behandlung von Lungenhochdruck | |
| JP7621220B2 (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| DE69133584T2 (de) | Vorrichtung zum Behandeln einen Lungengefässverengung und von Asthma | |
| US20220008436A1 (en) | Treprostinil administration by inhalation | |
| EP1178832B1 (de) | Neuartige arzneimittelkompositionen auf der basis von tiotropiumbromid und salmeterol | |
| CA2043077C (en) | Prostaglandin analogues for use in medicine | |
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE69428351T3 (de) | Systemische effekte der inhalation von stickstoffoxid | |
| DE69533190T2 (de) | Behandlung von pulmonaler vasokonstriktion und asthma | |
| EP2110126B9 (de) | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich | |
| DE69326849T2 (de) | Verwendung von humanem Atrio-natriuretischem Peptid zur Herstellung eines Medikaments zur Behandlung des Atemunwohlseinsyndroms bei Erwachsenen | |
| Stirt | Aminophylline is a diazepam antagonist | |
| DE112019000683T5 (de) | Intranasale epinephrin-formulierungen und verfahren zur behandlung von erkrankungen | |
| DE68904358T2 (de) | Prostaglandinanaloge zur verwendung in der medizin. | |
| DE3315356A1 (de) | Verwendung von prostaglandinanalogen | |
| EP1526870A1 (de) | Neue kombination von glucocorticoiden und pde-4-inhibitoren zur behandlung von atemwegserkrankungen, allergischen erkrankungen, asthma und copd | |
| DE19519056A1 (de) | Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation | |
| DE60301862T2 (de) | Kombinationsbehandlung bei akutem myokardinfarkt | |
| DE68907976T2 (de) | Verwendung eines Thromboxan-A2-Rezeptorantagonist zur Herstellung eines Arzeneimittels zur Behandlung pulmonarer Hypertonie, die durch Protamin-induzierte Neutralisation von Heparin verursacht wird. | |
| EP2581082B1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Status asthmaticus | |
| DE3880943T2 (de) | Verwendung von thromboxan-a2-antagonisten zur herstellung eines arzneimittels zur wiederherstellung von post-ischaemischer myokard-dysfunktion. | |
| DE60202299T2 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
| DE69128780T2 (de) | Verwendung von adenosine und adenosinederivate zur anästhesie | |
| CN120227329A (zh) | 用于治疗肺动脉高压的药物制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |